These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19596127)

  • 1. Gender effects in relapsing-remitting multiple sclerosis: correlation between clinical variables and gene expression molecular pathways.
    Achiron A; Gurevich M
    J Neurol Sci; 2009 Nov; 286(1-2):47-53. PubMed ID: 19596127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.
    Achiron A; Gurevich M; Snir Y; Segal E; Mandel M
    Clin Exp Immunol; 2007 Aug; 149(2):235-42. PubMed ID: 17488294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France.
    Debouverie M
    J Neurol Sci; 2009 Nov; 286(1-2):14-7. PubMed ID: 19691994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse.
    Achiron A; Feldman A; Mandel M; Gurevich M
    Ann N Y Acad Sci; 2007 Jun; 1107():155-67. PubMed ID: 17804543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
    Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
    Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical parameters and HHV-6 active replication in relapsing-remitting multiple sclerosis patients.
    Alvarez-Lafuente R; García-Montojo M; De las Heras V; Bartolomé M; Arroyo R
    J Clin Virol; 2006 Dec; 37 Suppl 1():S24-6. PubMed ID: 17276363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.
    Benedetti B; Rovaris M; Rocca MA; Caputo D; Zaffaroni M; Capra R; Bertolotto A; Martinelli V; Comi G; Filippi M
    Mult Scler; 2009 Jul; 15(7):789-94. PubMed ID: 19465450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
    Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical course of multiple sclerosis patients in Hong Kong.
    Lau KK; Wong WW; Sheng B; Yu IT; Fung BH; Li HL; Ma KF; Wong LK; Li PC
    J Neurol Sci; 2008 May; 268(1-2):78-82. PubMed ID: 18068191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
    Gurevich M; Gritzman T; Orbach R; Tuller T; Feldman A; Achiron A
    J Neuroimmunol; 2010 Apr; 221(1-2):87-94. PubMed ID: 20347159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis.
    Jung P; Beyerle A; Ziemann U
    Mult Scler; 2008 May; 14(4):553-6. PubMed ID: 18562509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.
    Gorman MP; Healy BC; Polgar-Turcsanyi M; Chitnis T
    Arch Neurol; 2009 Jan; 66(1):54-9. PubMed ID: 19139299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with the risk of secondary progression in multiple sclerosis.
    Koch M; Uyttenboogaart M; van Harten A; De Keyser J
    Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corpus callosum function in verbal dichotic listening: inferences from a longitudinal follow-up of Relapsing-Remitting Multiple Sclerosis patients.
    Gadea M; Marti-Bonmatí L; Arana E; Espert R; Salvador A; Casanova B
    Brain Lang; 2009 Aug; 110(2):101-5. PubMed ID: 19419759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.